Share
Doravirine-Islatravir (Idvynso)
All References
Filter by Category
- All References
- Clinical Studies
- Treatment-Naive
- Treatment-Experienced
- Switch/Simplification
- Dual Therapy
- Monotherapy
- PREP
- PEP
- Acute HIV
- Resistance/Virological Failure
- Pharmacology
- General Pharmacology
- Adverse Effects
- Drug Interactions
- Pregnancy/Women
- Pediatrics
- Review
- Azam MT, Azam MH, Khan MA, et al. Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment. Ther Adv Infect Dis. 2026;13:20499361261483928.
[PubMed Abstract] - Chahine EB, Koren DE, Samuel R, Van der Kloot H, Sherman EM. Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection. Ann Pharmacother. 2026;:10600280261472079.
[PubMed Abstract] - Colson AE, Mills AM, Ramgopal MN, et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet. 2026;407:611-21.
[PubMed Abstract] - Diamond TL, Grandhi A, Fuszard M, et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. J Infect Dis. 2026;234:e466-e476.
[PubMed Abstract] - Estrada V, Cabello-Clotet N. Beyond integrase: the rise of doravirine and islatravir in HIV management. Lancet. 2026;407:551-3.
[PubMed Abstract] - Hecksel CW, Walker SN, Raheem I, et al. Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase. ACS Infect Dis. 2026;12:3179-90.
[PubMed Abstract] - M Alghzawi H, Shah SZ, Abideen ZU, Ashraf MF. Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. HIV Res Clin Pract. 2026;27:2698230.
[PubMed Abstract] - Molina JM, Rizzardini G, Orrell C, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV. 2024;11:e369-e379.
[PubMed Abstract] - Orkin C, Mngqibisa R, Velez JD, et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet. 2026;407:599-610.
[PubMed Abstract] - Rockstroh JK, Kassim S, Paredes R, et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2026;13:e440-e451.
[PubMed Abstract] - Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. Current evidence on islatravir drug resistance and implications for future HIV treatment. Top Antivir Med. 2026;34:527-32.
[PubMed Abstract]